Skip to main content

The Funding Of Biopharmaceutical Research And Development

In Order to Read Online or Download The Funding Of Biopharmaceutical Research And Development Full eBooks in PDF, EPUB, Tuebl and Mobi you need to create a Free account. Get any books you like and read everywhere you want. Fast Download Speed ~ Commercial & Ad Free. We cannot guarantee that every book is in the library!

The Funding of Biopharmaceutical Research and Development

The Funding of Biopharmaceutical Research and Development Book
Author : David R Williams
Publisher : Elsevier
Release : 2013-10-31
ISBN : 1908818387
Language : En, Es, Fr & De

GET BOOK

Book Description :

The funding of biopharmaceutical research and development provides a comprehensive critical review of the funding of research and development (R&D) in the human biopharmaceutical market sector. It addresses both private and public funding sources available in the US and internationally. The biopharmaceutical market is among the most research-intensive market sectors globally. Clinical researchers face a multitude of public and private funding options with respect to bringing their idea or innovation to market. These funding options are continually changing and complex, and are expected to decrease in the near future. A lack of understanding of the scale, scope, and inner workings of the funding aspects of R&D can, at times, act as a barrier for all involved, and can slow down or even eliminate the R&D process. The book lessens these barriers by describing the theoretical underpinnings, present practice, and trends in R&D funding in this market sector, both in the US and internationally. This includes a review and discussion of public-private partnership activity and their inner-workings, noting the complementary relationship between public and private funding. The book also contains an overview of the inner-workings of strategic alliance activity, including the advantages and disadvantages for each party. It goes on to provide an outline of venture capital activity, detailing the methods by which venture capital firms raise capital and are organized, a description of the venture capital-entrepreneur arrangement, and the effects of this arrangement. The book also presents an overview of the IPO process and the various fates of firms going public. Presents a comprehensive view of the funding issues of R&D in this market sector, adopting a theory-to-practice approach A comprehensive and analytical review of the biopharmaceutical R&D literature and practice An overview of the various and competing/complementary theories of the firm and valuation methods as they apply to biopharmaceutical R&D

Biotech Industry

Biotech Industry Book
Author : Bryan Bergeron,Paul Chan
Publisher : John Wiley & Sons
Release : 2004-04-12
ISBN : 0471647578
Language : En, Es, Fr & De

GET BOOK

Book Description :

"The biotech industry is a complex, rapidly evolving, and criticalindustry. The industry holds great commercial and societal promise,but it is also filled with hype, confusion, and risks. Bergeron andChan do a remarkable job of providing a sweeping insightful, andprobing assessment of the current state and likely evolution ofthis global industry. This book is essential reading for theexecutive who desires a thorough understanding of this business andits potential."--John P. Glasser, Vice President and ChiefInformation Offers, Partners Healthcare System, Inc. "Bergeron and Chan have done a marvelous job integrating manydifferent perspectives to give the reader a coherent road map ofthe biotech industry for the next decade. This powerful book isanchored by numerous relevant examples that create a frameworkwhich any life sciences professional needs to understand. Ofparticular note is the compelling assessment of the IT industry andits impact on the life sciences as these industriesconverge."--Michael A. Greeley, Managing General Partner, IDGVentures. An in-depth examination of the growth and financing of thebiotechnology industry worldwide Biotech Industry: A Global, Economic, and Financing Overviewprovides a thorough look at the current state of the biotechnologyindustry, including where major research is being conducted, whereit's being applied, and where money and intellectual capital areflowing. Written by a renowned business columnist and an entrepreneurialscientist in the biotech area, this unique book gives Eos and othersenior-level managers an understanding of Asia's pivotal role inthe worldwide success of biotechnology commercialization, as wellas insight into the biotech market over the next decade.

Essays on Government Policy and Pharmaceutical Innovation

Essays on Government Policy and Pharmaceutical Innovation Book
Author : Margaret E. Blume-Kohout
Publisher : Unknown
Release : 2009
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

New drug therapies may deliver many social and economic benefits, but current levels of innovation across diseases may not be socially optimal. This dissertation investigates two mechanisms by which governments may influence pharmaceutical research and development (R & D) priorities: (1) public funding for life sciences research; and (2) prescription drug insurance, as in Medicare Part D. The author finds federal funding for life sciences research spurs non-federal investment in academic R & D as well as downstream drug development. Likewise, introduction of Medicare Part D increased both the number of drugs entering clinical trials and firm R & D expenditures for higher-Medicare-share drugs.

Outsourcing Biopharma R D to India

Outsourcing Biopharma R D to India Book
Author : P R Chowdhury
Publisher : Elsevier
Release : 2011-05-05
ISBN : 1908818018
Language : En, Es, Fr & De

GET BOOK

Book Description :

The trend of outsourcing to India for research and development is catching on fast. Over the last decade, worldwide pharmaceutical and biotechnology companies have made India their choice for a research destination. Initially R&D was inclined more towards developing products for the Indian market within the country. This led to several multinational companies opening up production plants in India, primarily due to the globalization of the Indian economy and offshoring jobs to India. Alongside, several global pharma-biotech majors ascertained large market requirements within the country and capitalized on the advantage of serving Indian customers. Strategies were devised to optimize operational expenses with the setting up of on-site R&D to develop products for local requirements. In view of this, this book seeks to explore various nuances of the outsourcing sector with respect to biopharma in India. Constitutes the first ever comprehensive insight on the Indian biopharma sector Provides a perspective based on practical hands-on legal experience Simply structured, clearly presented and free from excessive legal jargon

Entrepreneurship in Biotechnology

Entrepreneurship in Biotechnology Book
Author : Martin Grossmann
Publisher : Springer Science & Business Media
Release : 2012-12-06
ISBN : 3642574327
Language : En, Es, Fr & De

GET BOOK

Book Description :

Research and development of novel medicines for human therapy commonly takes over a decade before significant revenues from sales are forthcoming. How can biotechnology companies be founded and grow successfully in an industry with such extended innovation processes? The book investigates this problem and distinguishes three growth phases: From incorporation and start-up through collaborative R&D with large pharmaceutical firms to value creation from R&D pipelines to Public Offerings and product marketing. In this book a dynamic simulation model for testing different decision-making strategies is developed. For each phase the author identifies decision rules that provide for successful corporate growth.

Formulation tools for Pharmaceutical Development

Formulation tools for Pharmaceutical Development Book
Author : J E Aguilar
Publisher : Elsevier
Release : 2013-09-30
ISBN : 1908818506
Language : En, Es, Fr & De

GET BOOK

Book Description :

A range of new and innovative tools used for preformulation and formulation of medicines help optimize pharmaceutical development projects. Such tools also assist with the performance evaluation of the pharmaceutical process, allowing any potential gaps to be identified. These tools can be applied in both basic research and industrial environment. Formulation tools for pharmaceutical development considers these key research and industrial tools. Nine chapters by leading contributors cover: Artificial neural networks technology to model, understand, and optimize drug formulations; ME_expert 2.0: a heuristic decision support system for microemulsions formulation development; Expert system for the development and formulation of push-pull osmotic pump tablets containing poorly water-soluble drugs; SeDeM Diagram: an expert system for preformulation, characterization and optimization of tables obtained by direct compression; New SeDeM-ODT expert system: an expert system for formulation of orodispersible tablets obtained by direct compression; and 3D-cellular automata in computer-aided design of pharmaceutical formulations: mathematical concept and F-CAD software. Coverage of artificial intelligence tools, new expert systems, understanding of pharmaceutical processes, robust development of medicines, and new ways to develop medicines Development of drugs and medicines using mathematical tools Compilation of expert system developed around the world

Re inventing Drug Development

Re inventing Drug Development Book
Author : Jeffrey S. Handen
Publisher : CRC Press
Release : 2014-10-28
ISBN : 1466579986
Language : En, Es, Fr & De

GET BOOK

Book Description :

The biopharmaceutical industry has entered an era of unprecedented change and challenge, characterized by increasing pricing pressures, rising rates of attrition in the product development lifecycle, and decreasing scientific innovation. The most successful products are losing patent protection, and pipelines have been unable to fill the gap. This book explores the evolving definition of innovation in therapeutic product development and begins to examine its effects on the life sciences R&D industry. Historically, scientific innovation alone was sufficient to maintain ROI and deliver on unmet medical needs. However, with many forces now conspiring to increase pressures on the commoditization of drug development, industry support for truly novel, often high-risk development has eroded. This calls for a drastic redefinition of what "innovation" is. While innovation in the pharmaceutical R&D industry has historically been applied to major advances in therapy and unmet medical needs, we now need to see innovation increasingly defined in terms of financial, marketing (e.g. branded generics and emerging markets), pharmacoeconomic, and operational innovation. In this book, contributors drawn from the executive ranks of clinical development practitioners and stakeholders—from biopharmaceutical companies, clinical research organizations, academia, the financial community, and the patient perspective—have all come together to provide their expertise and visions. Their goal is to start a dialogue about ways to radically improve therapeutics development and get more and better medicines to the patients who need them, as fast as possible, in the most cost-efficient manner.

Modern Strategy for Preclinical Pharmaceutical R D

Modern Strategy for Preclinical Pharmaceutical R D Book
Author : David Cavalla
Publisher : John Wiley & Sons
Release : 1997-10-07
ISBN : 9780471971177
Language : En, Es, Fr & De

GET BOOK

Book Description :

The twentieth century has been a great success for modern medicine, and has resulted in the generation of a plethora of drugs to treat most common illnesses. However, in the light of increasing regulatory demands, spiralling costs and diminishing commercial returns, the question of how, when, where and whether to conduct pharmaceutical R&D has profound implications, and not just for those within the pharmaceutical industry. In response to these and other dilemmas, the authors define the processes involved in drug research, and examine the advantages and disadvantages of collaborative methods of drug research, and examine the roles that academia, CROs, small "biotechnology" companies and "research boutiques," and possibly even the "virtual research company" might play as contractors and collaborators.

Redefining how Pharmaceutical Innovation Gets Done

Redefining how Pharmaceutical Innovation Gets Done Book
Author : Vahid Montazerhodjat
Publisher : Unknown
Release : 2016
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

The productivity of research and development in the bio-pharmaceutical industry has been constantly declining since the early 2000's. One possible reason is that biomedical projects are risky, take a long time, and require significant investment. Hence, substantial capital has been shifted away from the bio-pharmaceutical industry to other industries that are perceived less risky, creating a funding gap for early-stage pharmaceutical R&D. Here, we investigate and improve upon a novel financing technique that has been proposed to facilitate the R&D funding in the bio-pharmaceutical industry. This new financing method is a clear example of rapidly evolving innovation in the financial industry, from which the bio-pharmaceutical industry can benefit tremendously. Apart from funding challenges, pharmaceutical companies have to clear regulatory hurdles before they can commercialize their treatments. These drug-regulatory standards require a specific balance of benefits vs. risks for a therapy to be approved, and do not currently take into account the severity of the disease that the therapy is targeting. In the second part of this thesis, we propose an objective and quantitative Bayesian decision analysis framework to incorporate patients' feedback into the drug-approval process, and propose adjustment to the approval standards based on disease severity. When launching their drug, pharmaceutical companies set the drug's price such that expected revenues offset the costs of all the projects, failed or successful, that were pursued in order to lead to this successful treatment resulting in costly treatment. Recently, some highly curative therapies with high price tags have emerged for diseases with large prevalence, such as hepatitis C. These high prices, coupled with the large size of the patient population, have created an unsupportable financial burden for insurance companies in order to cover the broadest patient population who could benefit from these drugs. Despite delivering breakthrough discoveries, the pharmaceutical companies producing these drugs have experienced a public backlash due to drug prices. In the last part of this dissertation, we introduce a new financing paradigm to address the issue of high aggregate costs for these highly curative therapies.

Pharmaceutical Innovation

Pharmaceutical Innovation Book
Author : Tomas E. Sanchez,Charles L. Scott
Publisher : Nova Science Publishers
Release : 2012
ISBN : 9781622570683
Language : En, Es, Fr & De

GET BOOK

Book Description :

Congress has exhibited a strong and ongoing interest in facilitating the development of new, innovative pharmaceuticals for the marketplace while reducing the cost of drugs to consumers. Policies pertaining to funding for research and development (R&D), intellectual property protection, and co-operative ventures have played an important role in the economic success of the pharmaceutical sector. Industry-specific legislation, also work to encourage innovation in the pharmaceutical sector while facilitating the entry of lower cost generic competition. While many factors contribute to innovation in the brand pharmaceutical industry and its ability to bring new and inventive products to the marketplace, this sector is facing significant issues associated with loss of revenue for additional R&D due to patent expirations and generic competition. This book examines the challenges associated with striking the proper balance between lower cost drugs and maintaining an innovative domestic pharmaceutical sector.

Biopharmaceutical Applied Statistics Symposium

Biopharmaceutical Applied Statistics Symposium Book
Author : Karl E. Peace,Ding-Geng Chen,Sandeep Menon
Publisher : Springer
Release : 2018-08-20
ISBN : 9811078297
Language : En, Es, Fr & De

GET BOOK

Book Description :

This BASS book Series publishes selected high-quality papers reflecting recent advances in the design and biostatistical analysis of biopharmaceutical experiments – particularly biopharmaceutical clinical trials. The papers were selected from invited presentations at the Biopharmaceutical Applied Statistics Symposium (BASS), which was founded by the first Editor in 1994 and has since become the premier international conference in biopharmaceutical statistics. The primary aims of the BASS are: 1) to raise funding to support graduate students in biostatistics programs, and 2) to provide an opportunity for professionals engaged in pharmaceutical drug research and development to share insights into solving the problems they encounter.The BASS book series is initially divided into three volumes addressing: 1) Design of Clinical Trials; 2) Biostatistical Analysis of Clinical Trials; and 3) Pharmaceutical Applications. This book is the first of the 3-volume book series. The topics covered include: A Statistical Approach to Clinical Trial Simulations, Comparison of Statistical Analysis Methods Using Modeling and Simulation for Optimal Protocol Design, Adaptive Trial Design in Clinical Research, Best Practices and Recommendations for Trial Simulations in the Context of Designing Adaptive Clinical Trials, Designing and Analyzing Recurrent Event Data Trials, Bayesian Methodologies for Response-Adaptive Allocation, Addressing High Placebo Response in Neuroscience Clinical Trials, Phase I Cancer Clinical Trial Design: Single and Combination Agents, Sample Size and Power for the Mixed Linear Model, Crossover Designs in Clinical Trials, Data Monitoring: Structure for Clinical Trials and Sequential Monitoring Procedures, Design and Data Analysis for Multiregional Clinical Trials – Theory and Practice, Adaptive Group-Sequential Multi-regional Outcome Studies in Vaccines, Development and Validation of Patient-reported Outcomes, Interim Analysis of Survival Trials: Group Sequential Analyses, and Conditional Power – A Non-proportional Hazards Perspective.

Towards Open Science

Towards Open Science Book
Author : Canada. Parliament. House of Commons. Standing Committee on Health
Publisher : Unknown
Release : 2018
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Towards Open Science book written by Canada. Parliament. House of Commons. Standing Committee on Health, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Biopharmaceutical Applied Statistics Symposium

Biopharmaceutical Applied Statistics Symposium Book
Author : Karl E. Peace,Ding-Geng Chen,Sandeep Menon
Publisher : Springer
Release : 2018-08-21
ISBN : 9811078262
Language : En, Es, Fr & De

GET BOOK

Book Description :

This BASS book Series publishes selected high-quality papers reflecting recent advances in the design and biostatistical analysis of biopharmaceutical experiments – particularly biopharmaceutical clinical trials. The papers were selected from invited presentations at the Biopharmaceutical Applied Statistics Symposium (BASS), which was founded by the first Editor in 1994 and has since become the premier international conference in biopharmaceutical statistics. The primary aims of the BASS are: 1) to raise funding to support graduate students in biostatistics programs, and 2) to provide an opportunity for professionals engaged in pharmaceutical drug research and development to share insights into solving the problems they encounter. The BASS book series is initially divided into three volumes addressing: 1) Design of Clinical Trials; 2) Biostatistical Analysis of Clinical Trials; and 3) Pharmaceutical Applications. This book is the second of the 3-volume book series. The topics covered include: Statistical Approaches to the Meta-analysis of Randomized Clinical Trials, Collaborative Targeted Maximum Likelihood Estimation to Assess Causal Effects in Observational Studies, Generalized Tests in Clinical Trials, Discrete Time-to-event and Score-based Methods with Application to Composite Endpoint for Assessing Evidence of Disease Activity-Free , Imputing Missing Data Using a Surrogate Biomarker: Analyzing the Incidence of Endometrial Hyperplasia, Selected Statistical Issues in Patient-reported Outcomes, Network Meta-analysis, Detecting Safety Signals Among Adverse Events in Clinical Trials, Applied Meta-analysis Using R, Treatment of Missing Data in Comparative Effectiveness Research, Causal Estimands: A Common Language for Missing Data, Bayesian Subgroup Analysis with Examples, Statistical Methods in Diagnostic Devices, A Question-Based Approach to the Analysis of Safety Data, Analysis of Two-stage Adaptive Seamless Trial Design, and Multiplicity Problems in Clinical Trials – A Regulatory Perspective.

Federal R d Drug Discovery and Pricing

Federal R d  Drug Discovery  and Pricing Book
Author : Wendy H. Schacht
Publisher : DIANE Publishing
Release : 2012-10-10
ISBN : 1437989268
Language : En, Es, Fr & De

GET BOOK

Book Description :

Public interest in approaches that might provide prescription drugs at lower cost, particularly for the elderly, has rekindled discussion over the role the federal government plays in facilitating the creation of new pharmaceuticals for the marketplace. The government traditionally funds R&D to meet the mission requirements of the federal departments and agencies. It also supports work in areas where there is an identified need for research, primarily basic research, not being performed in the private sector. Congressional initiatives have expanded to include the promotion of technological innovation to meet other national needs, particularly the economic growth that flows from the use of new and improved goods and services. Various laws facilitate commercialization of federally funded R&D through technology transfer, cooperative R&D, and intellectual property rights. Contents of this report: Overview; Government Support for R&D; Industrial R&D; Patents; Legislative Initiatives; NIH-University-Industry Collaboration; Pricing Decisions and Recoupment; Research Tools; Government Rights: Royalty Free Licenses and Reporting Requirements; Conclusion. Figures. This is a print on demand report.

Computer Aided Applications in Pharmaceutical Technology

Computer Aided Applications in Pharmaceutical Technology Book
Author : Jelena Djuris
Publisher : Elsevier
Release : 2013-04-10
ISBN : 1908818328
Language : En, Es, Fr & De

GET BOOK

Book Description :

Research and development in the pharmaceutical industry is a time-consuming and expensive process, making it difficult for newly developed drugs to be formulated into commercially available products. Both formulation and process development can be optimized by means of statistically organized experiments, artificial intelligence and other computational methods. Simultaneous development and investigation of pharmaceutical products and processes enables application of quality by design concept that is being promoted by the regulatory authorities worldwide. Computer-aided applications in pharmaceutical technology covers the fundamentals of experimental design application and interpretation in pharmaceutical technology, chemometric methods with emphasis of their application in process control, neural computing (artificial neural networks, fuzzy logic and decision trees, evolutionary computing and genetic algorithms, self-organizing maps), computer-aided biopharmaceutical characterization as well as application of computational fluid dynamics in pharmaceutical technology. All of these techniques are essential tools for successful building of quality into pharmaceutical products and processes from the early stage of their development to selection of the optimal ones. In addition to theoretical aspects of various methods, the book provides numerous examples of their application in the field of pharmaceutical technology. A comprehensive review of the current state of the art on various computer aided applications in pharmaceutical technology Case studies are presented in order to facilitate understanding of various concepts in computer-aided applications

Practical Leadership for Biopharmaceutical Executives

Practical Leadership for Biopharmaceutical Executives Book
Author : Jane Y Chin
Publisher : Elsevier
Release : 2011-05-05
ISBN : 1908818026
Language : En, Es, Fr & De

GET BOOK

Book Description :

The biohealthcare executive in upper-middle management confronts leadership challenges unique to their industry: they manage highly specialized knowledge workers and innovators, compete at the speed of technology, work in a highly regulated environment where "free speech" often does not apply due to patient safety and privacy concerns, and increasingly are leading virtual teams who may be located in different parts of the world. Practical leadership for biopharmaceutical executives is a guide that strips away the theory and meets head-on the practical leadership challenges these executives face on a daily basis, and provides these "innovator leaders" with the tools to lead effectively in the face of technological complexity. Focuses on personal leadership, where the executive has an opportunity to manage his/her own effectiveness as a leader and manager, and engage with their own career development and method of contribution within their chosen industry Discusses particularly the unique leadership challenges in biohealthcare: an industry that is at once highly innovative and emotive. Biohealthcare companies are often viewed with suspicion by the consumers who question corporate motives, and product marketing and sales practices. The effective biohealthcare leaders are well aware of these emotive features, and embody ethics through action - not just lip service Includes real life examples, including a series of both phone-based and email-based interviews of executives

An Introduction to Pharmaceutical Sciences

An Introduction to Pharmaceutical Sciences Book
Author : Jiben Roy
Publisher : Elsevier
Release : 2011-07-25
ISBN : 1908818042
Language : En, Es, Fr & De

GET BOOK

Book Description :

This textbook is written as a unified approach to various topics, ranging from drug discovery to manufacturing, techniques and technology, regulation and marketing. The key theme of the book is pharmaceuticals - what every student of pharmaceutical sciences should know: from the active pharmaceutical ingredients to the preparation of various dosage forms along with the relevant chemistry, this book makes pharmaceuticals relevant to undergraduate students of pharmacy and pharmaceutical sciences. This book explains how a particular drug was discovered and then converted from lab-scale to manufacturing scale, to the market. It explains the motivation for drug discovery, the reaction chemistry involved, experimental difficulties, various dosage forms and the reasoning behind them, mechanism of action, quality assurance and role of regulatory agencies. After having a course based on this book, the student will be able to understand: 1) the career prospects in the pharmaceutical industry, 2) the need for interdisciplinary teamwork in science, 3) the techniques and technology involved in making pharmaceuticals starting from bulk drugs, and 4) different dosage forms and critical factors in the development of pharmaceutical formulations in relation to the principles of chemistry. A few blockbuster drugs including atorvastatin, sildanefil, ranitidine, ciprofloxacin, amoxicillin, and the longest serving drugs such as aspirin and paracetamol are discussed in detail. Finally, the book also covers the important current pharmaceutical issues like quality control, safety, counterfeiting and abuse of drugs, and future prospects for pharmaceutical industry. Unified approach explaining drug discovery, bulk drug manufacturing, formulation of dosage forms, with pharmacological and therapeutic actions Manufacturing processes of representative active pharmaceutical ingredients and their chemistry plus formulation of dosage forms presented in this book are based on actual industrial processes Covers many aspects relevant to students of the pharmaceutical sciences or newly employed pharmaceutical researchers/employees. It contains summary information about regulatory agencies of different countries

A Biotech Manager s Handbook

A Biotech Manager s Handbook Book
Author : M O'Neill,M M Hopkins
Publisher : Elsevier
Release : 2012-05-02
ISBN : 1908818158
Language : En, Es, Fr & De

GET BOOK

Book Description :

A biotech manager's handbook lays out - in a simple, straightforward manner - for the manager or would-be entrepreneur the basic principles of running a biotech company. Most managers in biotechnology companies are working in their first company or in their first managerial role. Their expertise and experience in the scientific part of the work can be taken as a given but there is a whole range of other skills to be learned and areas of expertise to come to terms with. Small companies do not have big budgets to hire people or time to become an expert in so many areas. The book starts by outlining the state of the biopharmaceutical industry and goes on to explain the importance of planning (no matter what the size of the company). Succeeding chapters deal with the basics of intellectual property, perspectives from a university technology transfer office and how to raise some initial funding from an investor and entrepreneur. No other 'how to' manual exists for this sector Written by a range of expert professionals in each area, all in one book Is the only 'bench to bedside' book covering the whole spectrum of development

Open Source Software in Life Science Research

Open Source Software in Life Science Research Book
Author : Lee Harland,Mark Forster
Publisher : Elsevier
Release : 2012-10-31
ISBN : 1908818247
Language : En, Es, Fr & De

GET BOOK

Book Description :

The free/open source approach has grown from a minor activity to become a significant producer of robust, task-orientated software for a wide variety of situations and applications. To life science informatics groups, these systems present an appealing proposition - high quality software at a very attractive price. Open source software in life science research considers how industry and applied research groups have embraced these resources, discussing practical implementations that address real-world business problems. The book is divided into four parts. Part one looks at laboratory data management and chemical informatics, covering software such as Bioclipse, OpenTox, ImageJ and KNIME. In part two, the focus turns to genomics and bioinformatics tools, with chapters examining GenomicsTools and EBI Atlas software, as well as the practicalities of setting up an ‘omics’ platform and managing large volumes of data. Chapters in part three examine information and knowledge management, covering a range of topics including software for web-based collaboration, open source search and visualisation technologies for scientific business applications, and specific software such as DesignTracker and Utopia Documents. Part four looks at semantic technologies such as Semantic MediaWiki, TripleMap and Chem2Bio2RDF, before part five examines clinical analytics, and validation and regulatory compliance of free/open source software. Finally, the book concludes by looking at future perspectives and the economics and free/open source software in industry. Discusses a broad range of applications from a variety of sectors Provides a unique perspective on work normally performed behind closed doors Highlights the criteria used to compare and assess different approaches to solving problems

Strong Medicine

Strong Medicine Book
Author : Michael Kremer,Rachel Glennerster
Publisher : Princeton University Press
Release : 2016-05-31
ISBN : 0691171165
Language : En, Es, Fr & De

GET BOOK

Book Description :

From Nobel Prize–winning economist Michael Kremer and fellow leading development economist Rachel Glennerster, an innovative solution for providing vaccines in poor countries Millions of people in the third world die from diseases that are rare in the first world—diseases like malaria, tuberculosis, and schistosomiasis. AIDS, which is now usually treated in rich countries, still ravages the world's poor. Vaccines offer the best hope for controlling these diseases and could dramatically improve health in poor countries. But developers have little incentive to undertake the costly and risky research needed to develop vaccines. This is partly because the potential consumers are poor, but also because governments drive down prices. In Strong Medicine, Michael Kremer and Rachel Glennerster offer an innovative yet simple solution to this worldwide problem: "Pull" programs to stimulate research. Here's how such programs would work. Funding agencies would commit to purchase viable vaccines if and when they were developed. This would create the incentives for vaccine developers to produce usable products for these neglected diseases. Private firms, rather than funding agencies, would pick which research strategies to pursue. After purchasing the vaccine, funders could distribute it at little or no cost to the afflicted countries. Strong Medicine details just how these legally binding commitments would work. Ultimately, if no vaccines were developed, such a commitment would cost nothing. But if vaccines were developed, the program would save millions of lives and would be among the world's most cost-effective health interventions.